Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 25, 2023
Reporting Period: Event-based report regarding regulatory feedback received on September 25, 2023.
Key Financial Metrics
This filing is an event-based report (Item 8.01) and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event reported is the receipt of positive written feedback and guidance from the U.S. Food and Drug Administration (FDA). This feedback was received following the Company's Type-B pre-Investigational New Drug Application (IND) meeting.
Guidance, Outlook, and Risks
- Regulatory Outlook: The Company received positive feedback regarding questions submitted to the FDA, indicating progress in its drug development pipeline.
- Forward-Looking Statements: The filing contains forward-looking statements regarding future results, strategy, and plans. These are subject to risks and uncertainties that may cause actual results to differ materially.
- Risk Disclosure: Investors are cautioned not to place undue reliance on forward-looking statements. Additional risk factors are detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and subsequent Quarterly Reports on Form 10-Q.
Investor Verification Checklist
- Verify the specific details of the FDA feedback by reviewing the attached Press Release (Exhibit 99.1).
- Confirm the timeline for the subsequent submission of the Investigational New Drug (IND) application.
- Review the Company's most recent Form 10-K and 10-Q filings for current financial liquidity and cash runway, as this 8-K does not provide financial data.
- Monitor for updates on the Company's emerging growth company status and any changes to its regulatory strategy.